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Abstract: 
 
HIV-infected injection drug users (IDUs) often suffer from serious nutritional deficiencies. This 
is a concern because plasma levels of micronutrients such as vitamin B12, zinc, and selenium 
have been correlated with mortality risk in HIV-positive populations. Injection drug use also 
increases lipid peroxidation and other indicators of oxidative stress, which, combined with 
antioxidant deficiencies, can stimulate HIV-1 replication through activation of NF-κB  
transcription factors, while weakening immune defenses. As detailed herein, these prooxidant 
stimuli can also increase the pathogenic effects of HIV-1 by another mechanism, involving viral 
selenoproteins. Overlapping the envelope coding region, HIV-1 encodes a truncated glutathione 
peroxidase (GPx) gene (see #6 in reference list). Sequence analysis and molecular modeling 
show that this viral GPx (vGPx) module has highly significant structural similarity to known 
mammalian GPx, with conservation of the catalytic triad of selenocysteine (Sec), glutamine, and 
tryptophan. In addition to other functions, HIV-1 vGPx may serve as a negative regulator of 
proviral transcription, by acting as an NF-κB inhibitor (a known property of cellular GPx). 
Another potential selenoprotein coding function of HIV-1 is associated with the 3′ end of 
the nef gene, which terminates in a conserved UGA (potential Sec) codon in the context of a 
sequence (Cys-Sec) identical to the C-terminal redox center of thioredoxin reductase, another 
cellular regulator of NF-κB. Thus, in combination with known cellular mechanisms involving 
Se, viral selenoproteins may represent a unique mechanism by which HIV-1 monitors and 
exploits an essential micronutrient to optimize its replication relative to the host. 
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Article: 
 
Several studies have demonstrated that the intake or blood levels of various micronutrients are 
significantly correlated with survival in HIV-1 infection, both in HIV-infected injection drug 
users (IDUs), and in general HIV-positive populations (l-3). Of all micronutrients, the most 
widely documented and statistically significant correlation with HIV disease outcome has been 
demonstrated for selenium (Se) status, which has been correlated with various indicators of 
disease progression, and is an independent predictor of mortality in HIV infection (3-5), as 
reviewed previously (6). This is of particular interest, because Se, although classified as a 
mineral, is a potent dietary antioxidant, and its cellular actions are intimately linked to the redox 
status of the cell, and to the redox regulation of genes that are important for various immune cell 
functions (7). Thus, given an accumulating body of evidence that oxidative stress is a hallmark 
of AIDS (8,9), and an activator of HIV-1 replication in vitro (10,11), it is not surprising that Se 
should prove to be of critical importance in HIV-1 infection. 
 
SELENIUM AND CELLULAR IMMUNITY 
 
In addition to nonspecific incorporation as selenomethionine, Se can be specifically incorporated 
into proteins as the rare amino acid selenocysteine (Sec), the Se analogue of cysteine. In 
mammals, Se has many critical functions, including antioxidant defense, thyroid action, 
reproductive function, and immune function (12). These biologic functions of Se are generally 
associated with specific selenoproteins; for instance, Se is critical for antioxidant defenses 
largely because it is an essential component of Se-dependent glutathione peroxidases (GPx). 
 
It is now well established that adequate levels of Se are necessary for the immune system, and 
cellular immunity in particular, to function properly (7,13). Se supplementation increases the 
cytotoxicity of killer cells as well as their proliferation in response to mitogens and antigens (14), 
whereas Se deficiency has the opposite effect, and is commonly associated with impaired 
immune function (7). Correlations between CD4+ T-cell counts and plasma Se levels have been 
widely documented, most significantly in HIV-infected patients (6). Se also potentiates the 
action of the cytokine interleukin 2 (IL-2), by upregulating the IL-2 receptor (15). 
 
Significantly, the mRNA for a selenoprotein gene called Sps2, involved in biosynthesis of 
selenophosphate, the activated Se species required for formation of selenocysteine, is 
upregulated on activation of T lymphocytes (16); this suggests that selenoprotein synthesis is 
required for some aspect of T-cell function. Because cellular immunity is our primary defense 
against both cancer and viruses, a role of Se in cellular immune function represents a common 
factor in the known anticancer (17) and antiviral benefits of dietary Se (18). 
 
DRUG ABUSE, MALNUTRITION AND IMMUNE FUNCTION 
 
Injection drug users are a population known to be exceptionally prone to malnutrition, for several 
reasons. An addict's prime concern is obtaining the next drug dose; obtaining food is secondary. 
Furthermore, most IDUs are socially marginalized and impoverished, in part due to the cost of 
supporting their drug habit, so that the quality of their diet is often inadequate. These nutritional 
deficiencies associated with drug addiction have been linked to compromised immune function 
even in HIV-negative drug users (19), which is not surprising in light of the importance of 
nutrition for maintaining optimal immune function (20). 
 
Of particular significance for the role of antioxidants in HIV-positive IDUs is that injection drug 
use exerts an exceptional oxidant stress on the body and the immune system. In part because of 
tissue damage and cellular injury, drug abusers show increased lipid peroxidation products in 
blood, liver, and urine (21-23), and low serum thiol levels indicating increased oxidative stress 
are predictive of outcome in HIV-positive IDUs (24). This effect of drug abuse leads to an 
increased requirement for nutritional antioxidants, which is unlikely to be met in typical 
malnourished drug users. A study of heroin users showed significantly low urinary Se levels 
(25), which suggests that dietary Se intake is low or that absorption is impaired in IDUs. This 
would exacerbate the oxidative stress that is a direct consequence of injection drug use. 
 
The now well-established correlation between Se status and HIV-1 disease progression (3-6) 
should be particularly apparent in HIV-positive IDUs, in the light of the facts just reviewed. To 
summarize: 
 
Se is essential for cellular immunity, as well as for antioxidant defenses. 
 
Malnutrition is common in drug addicts. 
 
Injection drug use can be associated with increased oxidative stress and lipid 
peroxidation. 
 
HIV-I transcription is activated by oxidative stress, through the transcription factor 
nuclear factor KB (NF-κB). 
 
In essence, the multiple risk factors of increased oxidative stress and inadequate (dietary) 
antioxidant intake can activate HIV-1 replication through known mechanisms, while weakening 
immune defenses. The logic of this argument is supported by the finding that the most significant 
correlation to date between Se status and HIV-1 disease outcome was observed in a cohort of 
HIV-positive IDUs, in whom low plasma Se was associated with a 20-fold increased risk of 
AIDS-related mortality (3). 
 
THE CELLULAR SELENOPROTEINS GPx AND THIOREDOXIN REDUCTASE 
REGULATE TRANSCRIPTION FACTOR NF-κB   
 
In the cell nucleus, by binding to a specific DNA consensus sequence, the active form of NF-κB 
acts as a transcriptional activator of a number of immune-related genes, including various 
cytokines, adhesion molecules, and genes that regulate cell proliferation and apoptosis (26-28). 
By incorporating DNA sequences to which NF-κB can bind into its promoter region, HIV has 
evolved so that it can be activated by the same cellular factor that stimulates these various 
immune-related functions. 
 
The activity of NF-κB is regulated in a complex manner by cellular location and redox status 
(26). Initial activation in the cytosol occurs through separation of the inhibitory KB subunit I-κB, 
which exposes a nuclear translocation signal on NF-κB, so that active NF-κB dimers can enter 
the nucleus and bind to their cognate DNA sites. This cytosolic activation is stimulated by 
oxidative stress (e.g., peroxides), inflammatory cytokines (e.g., tumor necrosis factor-a) and 
various noxious stimuli including ultraviolet light and radiation, in all of which the formation of 
reactive oxygen species is a common factor. Thus, oxidative stress is a well-documented 
activator of NF-κB (26-28), and of HIV transcription through NF-κB activation (8-11). 
 
It is therefore not surprising that in cell culture studies Se, as a component of the selenoprotein 
GPx, has been consistently found to be an inhibitor of NF-κB activation, presumably due to the 
reduction of peroxide levels by GPx (11,28,29). However, although those and many other cell 
culture studies have demonstrated that, in general, oxidants stimulate whereas antioxidants 
inhibit NF-κB activation and HIV-1 transcription, activation of NF-κB does not involve 
exclusively oxidative stimuli. Despite the important role of oxidative stress in the cytosolic 
activation of NF-κB, to bind DNA in the nucleus, the thiol group of an active site cysteine 
residue of NF-κB must be in a reduced state (26). Thus, although oxidative stress appears to be a 
primary activator of NF-κB, this must be balanced by the action of selective cellular redox 
systems that, in the midst of this oxidative environment, can provide reducing power to maintain 
NF-κB in its active, reduced state. This reductive activation of NF-κB is one major functions of 
the selenoprotein thioredoxin reductase (TrxR) and its substrate thioredoxin (26,30). 
 
GPx and TrxR are two of the most widely distributed selenoproteins, and it is remarkable that 
both have been demonstrated to be potent regulators of NF-κB activity, and all the more so that 
they appear to have opposed functions, that is, GPx inhibits (11,28,29) whereas TrxR activates 
(26,30) NF-κB activity. It is difficult to say which of these two may predominate, because the 
well-documented inhibition of NF-κB by selenite in cell culture may be due in part to the direct 
formation of inactive Se adducts at relatively high concentrations (>5 μM), and thus, rather than 
being mediated entirely through selenoproteins, a portion of this inhibition may represent a 
unique effect of selenite ion (27). Nonetheless, compelling evidence indicates that, under normal 
physiologic conditions, the selenoproteins GPx and TrxR are major regulators of NF-κB activity. 
This is of considerable significance in the light of evidence presented here subsequently that 
HIV-1 encodes selenoprotein modules having distinct similarities to both GPx and TrxR. 
 
AN HIV-I-ENCODED SELENIUM-DEPENDENT GPx GENE 
 
An env gene variant associated with one of the potential -1 frameshift sites predicted in HIV-1 in 
1994 (31) was subsequently identified as a virally encoded homologue of GPx, the prototypical 
mammalian selenoprotein (6). This viral GPx (vGPx) module is encoded overlapping the HIV-1 
env gp41 coding region in the -1 reading frame; thus the gene was tentatively named env-fs, for 
env frameshift. It contains a single UGA codon (potentially encoding Sec) near the middle of a 
small but highly conserved novel open reading frame, with a conserved -1 frameshift signal near 
its 5' end. The UGA codon is well conserved in the predominant American and European 
subtype B, but is found to be an AGA (Arg) codon in most other HIV-1 subtypes, a substitution 
that may still be compatible with GPx activity (6). The translated HIV-1 env-fs sequence 
contains a common variant of the GPx active site consensus sequence spanning the catalytic Sec 
(U in Fig. 1). 
 
Using a sensitive multiple sequence comparison method, a strong similarity between the entire 
HIV-1-encoded env-fs sequence and the aligned set of GPx sequences was demonstrated. As 
previously aligned (6), the similarity score of this novel HIV sequence versus an aligned group 
of GPx sequences is five standard deviations (SD) above the average similarity score of 
randomized sequences of identical composition. That significance score increases to-6.3 SD 
based on the revised alignment shown in Figure 1. 
 
FIG. 1. Sequence alignment of HIV-1 env-fs sequence versus Se-dependent glutathione peroxidases. Sequences are 
single letter amino acid codes, with U as the symbol for selenocysteine, Sec, encoded by the UGA codon in RNA. 
GPx sequences are listed by Swiss-Prot database accession number. Env-fs amino acids identical to one or more of 
the aligned GPx sequences are shown as letters in the "match" line above the alignment; similar residues are 
indicated by an asterisk. Three active site regions that are adjacent in three-dimensional space are shown below the 
alignment, labeled R1 to R3. All three regions and their essential catalytic amino acids, Sec, Gin and Trp (U, Q and 
W respectively, shown highlighted in bold), are represented in the truncated env-fs sequence. The alignment is 
similar to that shown as Figure 1 of Taylor et al. (6) up to the end of R2, but is different beyond R2. There are three 
large deletions in env-fs relative to the GPx sequences, at the locations indicated by the symbols %, #, and ~ in the 
alignment. As computed using the alignment shown, that is, omitting the three internal GPx regions where there are 
major deletions in the truncated HIV-1 GPx homologue, the total similarity score of the env-fs sequence to the 
aligned GPx sequences is 6.3 standard deviations above the average similarity score computed for 100 optimally 
aligned randomly shuffled sequences of identical composition (see Experimental section). 
 
We examined alternative alignments of the C-terminal region of env-fs to GPx in the light of the 
bovine GPx crystal structure and its active site (Fig. 2), and identified the viral sequence 
matching a third GPx active site region with a conserved Trp (W), shown as region 3 (R3) in the 
alignment of Figure 1. This reveals a total of three significant internal deletions in the HIV-1 
sequence relative to the mammalian GPx sequences. These deletions in env-fs, involving 19, 11, 
and 41 residues, respectively, lie between the three conserved active site regions (YUG, GHQ, 
and W) and project away from the active site in three-dimensional (3-D) space (Fig. 2A, 2B). 
 
To assess this proposed homology in structural terms, a 3-D molecular model of the HIV-1 vGPx 
(Fig. 2) was made by homology modeling, based on the alignment of Figure 1 (32). This showed 
that all three deletions are structurally feasible, although the first and third deletions would 
involve loss of domains that participate in formation of the tetrameric GPx enzyme. This 
suggests that the HIV-1 GPx homologue probably does not function as a multimer, which would 
make it similar to the phospholipid hydroperoxide GPx, which acts as a monomer (12). The 
proposed homology is also strongly supported by the fact that the Trp (W) active site residue in 
R3 (Fig. 1) is highly conserved in HIV-1 sequences. This conservation also provides compelling 
theoretical evidence that this is a functional gene, because the UGO Trp codon in the -1 frame is 
in the context of the sequence UCUGGA, which encodes Ser-Gly in the HIV envelope protein. 
Due to the degeneracy of the genetic code, Ser could be encoded using any base in the third 
codon position (i.e., UCN), so the conservation of a U in this position in HIV-1 sequences can 
only be explained by a functional requirement, such as the need for the UGO in the -1 frame 
(there is no known RNA structural element spanning this UGO codon). This putative HIV-1 
vGPx gene has now been cloned and, when expressed as a selenoprotein in transfected 
mammalian cells, was found to yield as much as a 99% increase in GPx activity relative to 
controls (32). Furthermore, the Cys homologue (Sec to Cys mutant) of the vGPx has been 
expressed in bacteria and isolated; the purified 9-kd protein has significant GPx activity, 
although that activity is low, as would be expected for a Cys mutant of a Se-dependent GPx 
(unpublished data). 
 
 
 
 
FIG. 2. Molecular modeling studies of the putative HIV-1 glutathione peroxidase (GPx) module. (A) View of the 
protein backbone of the x-ray crystal structure of the bovine GPx dimer (1GP1.pdb) with C-terminal and internal 
regions that are deleted from the HIV-1 GPx homologue shown in red, and the regions retained in HIV-1 (env-fs in 
the alignment of Fig. 1) shown in green, with three conserved active site residues (Sec, Gin and Trp) highlighted in 
magenta, with side chains displayed. The deleted regions (red) include a helix involved in dimer formation (bottom, 
center) and another region (top) that is involved in dimer and tetramer formation (tetramer not shown). The catalytic 
core of the enzyme is conserved in the truncated HIV-1 homolog. (B) A spacefill view of the protein backbone of 
the GPx monomer, colored as in A, except that the catalytic triad of Sec, Gin and Trp are shown in CPK colors. The 
deleted regions (red) all lie outside of the catalytic core domain. (C) Left: An all-atom homology model of the 
putative HIV-1 GPx with the deleted (red) regions shown in B removed and the resulting gaps reconnected by loop 
remodeling, giving a continuous peptide backbone matching the HIV-1 sequence (env-fs in Fig. 1). The active site 
triad is shown in CPK colors, with the Se atom in yellow. A cluster of basic residues (one Lys and several His) is 
shown in blue. Right: A similarly oriented and rendered all-atom view of the bovine GPx structure. The basic 
residues (blue) are all Arg, at least one of which is involved in binding glutathione. The HIV-1 GPx homologue, 
although highly truncated, includes the complete catalytic core of the enzyme, but it is likely to function as a 
monomer due to the deletion of regions involved in tetramer formation in the cellular GPx enzyme. The alignment 
of Figure 1 is structurally feasible, because the locations of the internal deletions permit the rest of the core structure 
to be maintained (32). 
 
THE 3' TERMINAL OF HIV-1 nef IS A UGA CODON IN A MOTIF IDENTICAL TO 
THE TrxR C-TERMINAL REDOX CENTER 
 
As detailed previously (18), the 3'-terminal UGA codon of nef is highly conserved in the known 
group M HIV-1 isolates (in >99% of known sequences), which is a unique feature of HIV -1 
compared with HIV -2 and SIV nef genes, in which UAA and UAG stop codons are also found 
at the 3' end of nef in various strains and subtypes, with no particular bias. Conservation of this 3' 
-terminal UGA codon is perhaps the most striking difference between the nef gene of the more 
pathogenic HIV-] versus that of the other primate retroviruses. A selenoprotein coding function 
is a simple and appealing hypothesis, particularly because HIV- J encodes a vGPx gene upstream 
in the env region (6,32). Preliminary evidence suggests that readthrough suppression of the nef 3' 
UGA codon can occur in vivo, and that in vitro this effect is Se dependent (33). Furthermore, 
additional results consistent with 75Se incorporation in a nef isoform during in vitro translation of 
a patient-derived nef isolate have been obtained (Benjamin Blumberg, personal communication). 
 
Because nef is highly expressed as an early gene, and no frameshift is required to encounter this 
in-frame 3'-terminal UGA codon during nef protein synthesis, we previously suggested that 
readthrough of this UGA codon, leading to sequestration of Sec in a nef selenoprotein isoform, 
might contribute to nef-associated pathogenicity of HIV-1 (18,31). However, until recently, there 
was little basis for developing a hypothesis as to the possible function of this nef isoform, other 
than a potential pathogenic role in intracellular Se depletion by the above mechanism. 
 
The discovery that TrxR is a selenoprotein presents an intriguing possibility. Another feature of 
the nef 3' terminal is a conserved Cys residue immediately preceding the UGA codon. Thus, this 
HIV-1 encoded sequence is identical to that of the redox center of TrxR, where a geminal Cys-
Sec pair al the protein C-terminal has been shown to be essential for the redox activity of TrxR 
(30). In addition, a sequence downstream of the UGA codon in nef, RRGLGGT(X7)CCI, is quite 
similar to the sequence of a second disulfide redox center located near the N-terminal (#52-65) 
of TrxR, RWGLGGTC(X4)CI. 
 
It must be remembered that nef, along with tat and rev, is ex pressed early in the cell infection 
cycle, at a point when HIV needs 10 activate its transcription. If this hypothetical selenoprotein 
isoform or nef can, like TrxR itself, contribute to activation of NF-κB, while reducing cellular 
GPx levels through Sc sequestration (thereby producing oxidative activation of NF-K B), that 
would be perfectly consistent with the viral agenda at that point in the infection cycle, as 
exemplified by the transactivating effect of the HIV tat gene that is expressed simultaneously 
with nef. Thus, in the case of nef, we predict that HIV-1 is using a viral selenoprotein for NF-κB 
activation, whereas the HIV-1 vGPx—a late gene—would be expected to deactivate NF-κB by 
decreasing oxidant tone. Notably, another role of TrxR is in the synthesis or 
deoxyribonucleotides, through ribonucleolide reductase (30). DNA synthesis is certainly another 
function that could help explain why HIV-1 might encode a module with TrxR-like activity. This 
would be consistent with the enhancement or infectivity and stimulation or proviral DNA 
synthesis activities that have been demonstrated for the HIV-1 nef gene (34). 
 
AN HIV-1-ENCODED NF-κB HOMOLOGUE? 
 
An earlier study (31) noted the existence of a potential HIV-1 selenoprotein module potentially 
expressed by a -1 frameshift from the protease coding region, which was thus later named pro-fs 
(18). This was predicted to be a very basic, positively charged protein (pI = 11), suggesting a 
nucleic acid binding protein, database searches produced matches to various DNA binding 
proteins. In particular, Taylor el al. suggested a similarity to the papillomavirus E2 DNA binding 
protein, which has a conserved Cys residue that aligns with the highly conserved UGA codon of 
pro-fs (31). 
 
This hypothesis can be refined in light of data contained in a paper that was in press (26) at the 
time our 1994 paper (31) was submitted. Significantly, like the E2 proteins, members of the NF-
κB family of transcription factors also contain an essential Cys residue in their DNA-binding 
domain; this Cys is in fact the amino acid that TrxR maintains in a reduced (thiol) state in order 
for NF-κB to bind to DNA (26,30). From a comparison of the alignment of pro-fs versus the E2 
proteins in Figure 9 of Taylor et al. (31) with the alignment versus the DNA-binding "NRD" 
domain of the NF-κB family (Fig. 3), it is evident that the alignment or pro-fs to the NRD 
domain gives a tighter alignment, with no gaps in the primary DNA con tact region. The 
statistical significance of this similarity relative to randomly shuffled sequences is 4.5 SD for the 
region shown in Figure 3. 
 
 
FIG. 3. The HIV-1 pro-fs sequence (31) compared with a multiple alignment of the DNA binding domain of the 
NF-κB/Rel/Dorsal (NRD) family of transcription factors; the region involved in sequence-specific DNA recognition 
is indicated. The following amino acid similarities are highlighted in bold. Basic: R, K, H (Arg, Lys, His); 
Aromatic: Y, F (Tyr, Phe); Hydrophobic: L, I, V, F (Leu, lie, Val, Phe); Acid/amide: D, E, N, Q (Asp, Glu, Asn, 
Gin). Pro-fs amino acids identical to one or more of the aligned NRD sequences are shown as letters in the "match" 
line above the alignment; similar residues are indicated by *. The underlined C in pro-fs, aligned with the conserved 
C of the NRD domain, is a potential Sec residue, encoded by a highly conserved UGA codon in HIV-1 . Statistical 
significance of the sequence similarity is 4.5 standard deviations relative to that expected for random sequences of 
identical composition. The region shown above corresponds to positions 8-46 of the alignment for Domain #1239 at 
the ProDom website (www.toulouse.inra.fr/prodom/doc/prodom.html), from which the full names of the NRD 
sequences shown can be obtained . 
 
The protein sequence encoded in this overlapping gene region of protease is highly conserved in 
HIV-1 sequences. which cannot be explained by any known coding or functional requirement of 
HIV. Furthermore, using a standard assay, we have established that the predicted -1 frameshift 
site in the HIV-1 protease gene (31) is active in vitro (Fig. 4). This frameshift occurs just 
upstream of the pro-fs sequence (RYRSRC) that matches the "signature" of the NRD domain 
(RFRYXC). Given the combination of an active frameshift into this novel genomic region of 
HlV-1, and a highly conserved sequence in the overlapping -l frame, there is little reason to 
doubt that this sequence is expressed in vivo. 
 
 
FIG. 4. In vitro translation (IVT) assay showing -1 frameshift activity induced by a fragment of the HIV-1 protease 
gene (31) when inserted into the RW-201 vector. In addition to a major low molecular weight "zero frame" 
translation product (about 40 kd, shown as M), if the insert can induce -1 ribosomal frameshifting, higher molecular 
weight minor products (full length product at about 150 kd, shown as FS) are observed. Lane 1: IVT of RW-201 
with an insert from a high efficiency (20%) -1 frameshift sequence from the mouse mammary tumor virus, used as a 
positive control. Lane 2: IVT of RW-201 with a pro-fs insert, with the UGA stop codon in the -1 frame of the insert 
mutated to a sense codon to permit readthrough in the -1 frame. Note the FS band similar to lane 1 but less intense. 
No bands were visible in control lanes with no DNA added (not shown). See Experimental Section for details. 
 
From the gene alignment, it is clear that the protease-processed form of pro-fs could be at the 
most a minimal DNA-binding domain, and lack the transcriptional activating (TA) domain of 
NF-κB. By analogy to the E2 proteins (31), a DNA-binding domain alone could function as a 
repressor by preventing the complete protein (DNA-binding plus TA domain) from binding, or 
by forming inactive heterodimers. Thus, pro-fs may function as a transcriptional silencer or 
repressor, which could serve to maintain latency in an infected cell, that is, keep the provirus 
from being overexpressed, perhaps to evade immune surveillance. In essence, processed pro-fs 
could function as an antagonist to NF-κB, which would be consistent with the clinical data on Se 
status and HIV-1 disease progression and outcome (3-6). 
 
CONCLUSIONS 
 
Not only does HIV-1 appear to encode homologues or catalytic motifs of selenoproteins known 
to regulate NF-κB, that is, its own GPx and a module in nef that is identical to the TrxR "redox 
center," but it actually may encode its own highly truncated NF-κB homologue (pro-fs), that has 
Se instead of S in its DNA-binding domain. 
 
Although the precise mechanisms by which HIV-1 may recode specific UGA codons as sense 
codons for Sec have not yet been established, the sequence similarities to known selenoproteins, 
high degree of conservation of certain UGA codons, and demonstrated enzyme activity in the 
case of the HIV-1 GPx (32), strongly suggest that HIV-1 is able to do so. Potential RNA 
structures that may be involved in Sec insertion have been identified (including pseudoknot 
associated with UGA codons), and preliminary evidence of Se-dependent readthrough 
suppression of the 3' UGA codon of nef is promising (33). More research on this question is 
obviously needed. 
 
By our interpretation, the results of 75Se labeling of HIV-infected cells reported by Gladyshev et 
al. (35), contrary to those authors' conclusions, are actually highly consistent with the possibility 
of in vitro expression of one or more of the predicted HIV-1 selenoproteins. In HIV-infected 
cells, Gladyshev et al. noted a distinct decline in levels of cellular selenoproteins—which is 
exactly what the HIV selenoprotein theory predicts (18,3l)-and an increase in "low molecular 
mass" Se- labeled material. Although they did not explicitly identify the actual mass range in 
question, it is evident from their data (35) (Fig. 1 B) that much of this novel 75Se-labeled material 
lies immediately above the 6-kd band that they identify (page 836) as the lowest 75Se-labeled 
band in uninfected cells. Hence, their conclusion that this result disproves the possibility of HIV-
encoded selenoproteins seems premature considering that the predicted masses of the protease 
processed pro-fs and env-fs (vGPx) are in the range of 7 to 9 kd. ft is precisely this 9-kd form of 
env-fs that has been shown by Zhao et al. (32) to posses GPx enzyme activity. 
 
Because NF-κB is a central factor in HIV-1 gene regulation and is also regulated by cellular 
selenoproteins and redox status, it is not really surprising that HIV-1 would have evolved to 
participate directly in those regulatory processes, by encoding its own selenoprotein modules. To 
understand fully interactions between HIV-1 and risk factors like malnutrition, Se status, and 
oxidative stress associated with drug abuse, this novel Se-based mechanism of HIV-1 gene 
regulation and pathogenesis will have to be fully elucidated. 
 
EXPERIMENTAL SECTION 
 
Sequence Analysis 
 
Statistical significance of similarity between a query sequence (i.e., env-fs or pro-fs) and a 
prealigned protein family (GPx or NRD domain, respectively) was assessed using the 
BlockAlign program (Zhang, Kececioglu and Taylor, unpublished). This program produces an 
optimal, gapped alignment of a probe sequence against an exiting sequence alignment. By 
random shuffling of the query sequence, the average similarity score for optimally aligned 
random sequences of identical composition can be calculated. Significance is calculated a the 
distance of the actual core from the average random score in standard deviation. The blosum62 
amino acid similarity matrix was used, with gap creation and gap extension penalties of 6, 2 for 
Figure 1 and 10, 2 for Figure 3. Sec residues were treated as Cys for the purpose of these 
calculations. 
 
Molecular Modeling 
 
The SYBYL program (Tripos Assoc., St. Louis, MO, U.S.A.) was used to build the putative 
HIV-1 vG Px homology model, starting from the bovine cellular GPx X-ray crystal structure, file 
J GP I from the Brookhaven Protein Database. The model was constructed based on the 
alignment of Figure 1, using the biopolymer protein loop option to reconnect regions where 
deletions were predicted from the alignment. The final model was minimized using the Kollman 
united atom and all-atom force fields, with parameters for Sec estimated by analogy to Cys and 
from ab initio molecular orbital calculations on methyl selenol using the Gauian 94 program 
(Gaussian, Inc., Pittsburgh, PA, U.S.A.). 
 
In Vitro -1 Frameshift Assay 
 
A region of the HIV-1 pol gene, encompassing about 60 nucleotides spanning the potential 
frameshift site (31) (Fig. 4) was amplified with polymerase chain reaction from a laboratory 
strain of HIV-1, pBH-10 (vector obtained from the NIH AIDS Research and Reference Reagent 
Program, Ogden BioServices, Rockville, MD, U.S.A.), with incorporation of HindIII and Apal 
restriction sites in upstream and downstream oligonucleotide primers, respectively. The resulting 
protease sequence fragment was cloned into HindIII and Apal-digested pRW201 vector and on 
ligation with T4 DNA ligase, the recombinant plasmids (pro-fs-RW20 I) were transformed into 
Escherichia coli K-12 SU1675. The positive clones were confirmed and junctions were verified 
by sequencing the inserts in both directions. In vitro translation was performed by coupled 
reticulocyte lysate (TNT system, Promega, Madison, Wl, U.S.A.) with 1 μg of circular pro-fs-
RW201 plasmid. Briefly, multiple 25 μl in vitro reactions were set up with and without RW20 I 
plasmid DNA added to 20 μl rabbit reticulocyte lysate mix, which includes T7 RNA polymerase 
and charged aminoacyl tRNAs. 35S-Met label and water were added to a final volume of 25 μL 
and incubated at 30°C for 90 minutes. After adding the SDS-PAGE sample loading buffer the 
samples were denatured at 100°C for 3 minutes and then separated on 10% SDS-PAGE gels for 
60 to 90 minutes at 90 V. The translation reaction products were electroblotted onto a neutrally 
charged nylon membrane for 35 minute at 23 V using the Semi-Phor System (Pharmacia-
Upjohn, Kalamazoo, MI, U.S.A.). Finally, the membranes were exposed to X-OMAT Kodak x- 
ray film (Eastman-Kodak, Rochester, NY, U.S.A.) and developed. The film was then canned 
using the IS-1000 Digital Imaging System (Alpha Innotech Corp., San Leandro, CA, U.S.A.). 
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